The Genentech Cell Line Screening Initiative (gCSI)
The Genentech Cell Line Screening Initiative (gCSI) was undertaken independently of CCLE and GDSC to to address the concerns of inconsistencies across large-scale pharmacogenomic studies. In gCSI, Genentech independently characterized the response of 410 cancer cell lines to a subset agents tested by GDSC and CCLE. Genentech also evaluated three specific aspects of the screening protocols that are relevant to measured drug response: readout of cell viability (metabolic versus DNA content), seeding density strategy, and cell culture media conditions.
|Pharmacological||CellTiter Glo||Yes||AUC, IC50|
|mRNA Expression||Illumina RNA-seq||Yes||VSN/DESeq counts, RPKM|
|DNA Copy Number||Illumina 2.5M SNP||Yes||PICNIC|